Could one blood thinner be enough after a heart attack? new trial aims to find out

NCT ID NCT07583784

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two approaches to blood thinning after a heart attack in patients with atrial fibrillation. One group gets two blood thinners (a DOAC plus clopidogrel), while the other gets only one (a DOAC alone). The goal is to see if using just one drug reduces bleeding risks without increasing the chance of another heart attack or stroke. About 860 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Direct oral anticoagulants (apixaban, edoxaban, or rivaroxaban) with or without clopidogrel
What this could lead to
If successful, this could show that using only one blood thinner is safer and just as effective as two after a heart attack in people with atrial fibrillation, potentially reducing bleeding complications.
What could go wrong
This is a relatively early-stage trial with 860 participants, and the results may not apply to all patients. There is a risk that single therapy might not prevent future heart attacks or strokes as well as dual therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AF - ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, Gwangju, 61469, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.